First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma

First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma

Portfolio

WAVRE, Belgium — 29 April 2020: iSTAR Medical SA, a clinical-stage medical device company pioneering truly biocompatible solutions for glaucoma, today announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIjectTM. Both studies showed consistently outstanding reduction of intraocular pressure (IOP) and reduced need for IOP-lowering medication in over 50 patients with open angle glaucoma, following standalone MINIject implantation.